Karyopharm's Selinexor Combination Therapy for Myelofibrosis to Debut at ASCO 2026
Event summary
- Karyopharm's Phase 3 SENTRY trial results for selinexor + ruxolitinib in myelofibrosis selected for late-breaking oral presentation at ASCO 2026.
- Trial evaluated 60 mg selinexor weekly vs. placebo in JAK inhibitor-naïve myelofibrosis patients with platelet counts >100 x 109/L.
- Co-primary endpoints: spleen volume reduction ≥35% at week 24 and change in absolute total symptom score over 24 weeks.
- Presentation scheduled for June 2, 2026, with abstract release at 8:00 a.m. ET.
- Dr. John Mascarenhas of Mount Sinai to present findings.
The big picture
Karyopharm's ASCO presentation represents a critical validation milestone for selinexor's expansion into myelofibrosis, a rare blood cancer with limited treatment options beyond JAK inhibitors. The Phase 3 SENTRY trial results could position selinexor as a potential combination therapy leader in this high-unmet-need indication. Success here would diversify Karyopharm's oncology portfolio beyond its current multiple myeloma and DLBCL indications.
What we're watching
- Clinical Efficacy
- Whether the selinexor combination demonstrates superior spleen volume reduction and symptom improvement over ruxolitinib alone.
- Regulatory Pathway
- The pace at which Karyopharm could pursue regulatory approval for selinexor in myelofibrosis based on these results.
- Commercial Strategy
- How positive data might position selinexor as a potential first-line therapy in myelofibrosis, expanding its market potential.
Related topics